MedTrace Logo

Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)

NCT02141581 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2018-05-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the responses to licensed trivalent, inactivated influenza vaccine (TIV) delivered by different routes: intramuscular (IM) and intradermal (ID) and to the live, attenuated influenza vaccine (LAIV) administered intranasally -- all given to generally healthy male and female adult volunteers.

Conditions

Interventions

BIOLOGICAL

Fluzone® (IM)

This vaccine is given intramuscularly (IM)

BIOLOGICAL

Fluzone® Intradermal (ID)

This vaccine is given intradermally (ID)

BIOLOGICAL

2011-2012 FluMist®

This vaccine is given intranasally

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Stanford University

    lead OTHER

Principal Investigators

  • Cornelia L Dekker, MD · Stanford University

  • Harry B Greenberg, MD · Stanford University

  • Xiaosong He, PhD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
34 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02141581 on ClinicalTrials.gov